Andreas Müller

Dr. Andreas Müller

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2013 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
DBDaniel C. Betticher
Daniel C. Betticher
GDGeoffrey Delmore
Geoffrey Delmore
UBUrs Breitenstein
Urs Breitenstein
SASandro Anchisi
Sandro Anchisi
BZBeatrice Zimmerli-Schwab
Beatrice Zimmerli-Schwab
RTRalph R. Trueb
Ralph R. Trueb


10 October 2016 in BMC Cancer
Verified
Journal Article
Open access
PDF file
O(on behalf of the Swiss Group for Clinical Cancer Research (SAKK)
on behalf of the Swiss Group for Clinical Cancer Research (SAKK)
CRChristoph Rochlitz
Christoph Rochlitz
MBMartin Bigler
Martin Bigler
RMRoger von Moos
Roger von Moos
JBJürg Bernhard
Jürg Bernhard
RWRalph Winterhalder
Ralph Winterhalder
Adding bevacizumab to chemotherapy improves response rates and progression-free survival (PFS) in metastatic breast cancer (mBC). We aimed to demonstrate decreased toxicity with metronomic chemotherapy/bevacizumab compared with paclitaxel/bevacizumab. This multicenter, randomized phase III trial compared bevacizumab with either paclitaxel (arm A) or daily oral capecitabine-cyclophosphamide (arm B) as first-line treatment in patients with HER2-negative advanced breast cancer. The primary endpoint was the incidence of selected grade 3–5 adverse events (AE) including: febrile neutropenia, infection, sensory/motor neuropathy, and mucositis. Secondary endpoints included objective response rate, disease control rate, PFS, overall survival (OS), quality of life (QoL), and pharmacoeconomics. The study was registered prospectively with ClinicalTrials.gov, number NCT01131195 on May 25, 2010. Between September 2010 and December 2012, 147 patients were included at 22 centers. The incidence of primary endpoint-defining AEs was similar in arm A (25 % [18/71]; 95 % CI 15–35 %) and arm B (24 % [16/68]; 95 % CI 13–34 %; P = 0.96). Objective response rates were 58 % (42/73; 95 % CI 0.46–0.69) and 50 % (37/74; 95 % CI 0.39–0.61) in arms A and B, respectively (P = 0.45). Median PFS was 10.3 months (95 % CI 8.7–11.3) in arm A and 8.5 months (95 % CI 6.5–11.9) in arm B (P = 0.90). Other secondary efficacy endpoints were not significantly different between study arms. The only statistically significant differences in QoL were less hair loss and less numbness in arm B. Treatment costs between the two arms were equivalent. This trial failed to meet its primary endpoint of a reduced rate of prespecified grade 3–5 AEs with metronomic bevacizumab, cyclophosphamide and capecitabine.

1 August 2007 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
BKB Klaeser
B Klaeser
OWO Wiederkehr
O Wiederkehr
DKD Koeberle
D Koeberle
AMAndreas Müller
Andreas Müller
BBB Bubeck
B Bubeck
BTB Thuerlimann
B Thuerlimann
Background: Positron emission tomography with 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG–PET) is an accurate imaging modality for the staging of breast cancer. The aim of this study was to determine the potential therapeutic impact of pre- and postoperative FDG–PET in patients with clinically intermediate or high-risk breast cancer. Patients and methods: One hundred and fourteen patients with newly diagnosed breast cancer were examined before (73) or after (41) surgery. Patient data were translated into three scoring sheets corresponding to information available before positron emission tomography (PET), after PET and after further diagnostic tests. Three medical oncologists independently reviewed the retrospectively acquired patient data and prospectively made decisions on the theoretically planed treatment for each time point, according to the recommendations of St Gallen Consensus Guidelines 2005. Results: FDG–PET changed the planed treatment in 32% of 114 patients. In 20% of cases, therapeutic intention (curative versus palliative) was modified. Radiation treatment planning was changed in 27%, surgical planning in 9%, chemotherapy in 11% and intended therapy with bisphosphonates in 13% of all patients. Conclusion: Based on current treatment guidelines, FDG–PET, as a staging procedure in patients with newly diagnosed clinically intermediate or high-risk breast cancer examined pre- and postoperatively, may have a substantial therapeutic impact on treatment planning.

1 June 2014 in The Breast
Verified
Journal Article
Closed access
ATArnoud J Templeton
Arnoud J Templeton
KRKarin Ribi
Karin Ribi
CSChristian Surber
Christian Surber
HSHong Sun
Hong Sun
SSShu-Fang Hsu Schmitz
Shu-Fang Hsu Schmitz
TRThomas Ruhstaller
Thomas Ruhstaller

13 April 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
T(The Swiss Group for Clinical Cancer Research (SAKK)
The Swiss Group for Clinical Cancer Research (SAKK)
BPBernhard C. Pestalozzi
Bernhard C. Pestalozzi
CTChristoph Tausch
Christoph Tausch
KDKonstantin J. Dedes
Konstantin J. Dedes
CRChristoph Rochlitz
Christoph Rochlitz
SAStefan Aebi
Stefan Aebi
To evaluate the effect of Recurrence Score® results (RS; Oncotype DX® multigene assay ODX) on treatment recommendations by Swiss multidisciplinary tumor boards (TB). SAKK 26/10 is a multicenter, prospective cohort study of early breast cancer patients: Eligibility: R0-resection, ≥10% ER+ malignant cells, HER2–, pN0/pN1a. Patients were stratified into low-risk (LR) and non-low-risk (NLR) groups based on involved nodes (0 vs 1–3) and five additional predefined risk factors. Recommendations were classified as hormonal therapy (HT) or chemotherapy plus HT (CT + HT). Investigators were blinded to the statistical analysis plan. A 5%/10% rate of recommendation change in LR/NLR groups, respectively, was assumed independently of RS (null hypotheses). Two hundred twenty two evaluable patients from 18 centers had TB recommendations before and after consideration of the RS result. A recommendation change occurred in 45 patients (23/154 (15%, 95% CI 10–22%) in the LR group and 22/68 (32%, 95% CI 22–45%) in the NLR group). In both groups the null hypothesis could be rejected (both p < 0.001). Specifically, in the LR group, only 5/113 (4%, 95% CI 1–10%) with HT had a recommendation change to CT + HT after consideration of the RS, while 18/41 (44%, 95% CI 28–60%) of patients initially recommended CT + HT were subsequently recommended only HT. In the NLR group, 3/19 (16%, 95% CI 3–40%) patients were changed from HT to CT + HT, while 19/48 (40%, 95% CI 26–55%) were changed from CT + HT to HT. There was a significant impact of using the RS in the LR and the NLR group but only 4% of LR patients initially considered for HT had a recommendation change (RC); therefore these patients could forgo ODX testing. A RC was more likely for NLR patients considered for HT. Patients considered for HT + CT have the highest likelihood of a RC based on RS.